P. Barretina-Ginesta

Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer

Á. Arcusa, I. Bover, L. Vidal, 2019, Anti-cancer drugs.

Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC) (GEICO 1205/NOVA TRIAL).

I. Bover, L. Vidal, M. Gil-Martin, 2015 .

Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study

J. Cueva, A. Vivancos, J. López-Guerrero, 2022, Journal of personalized medicine.

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

B. Monk, K. Jardon, I. Vergote, 2019, The New England journal of medicine.

Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).

C. Schade-Brittinger, F. Marmé, I. Vergote, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.

R. Dienstmann, A. Gil-Moreno, J. Piulats, 2019, Gynecologic oncology.